Galectin-related protein, a key contributor, drives diabetes-associated neuropathic pain.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41359849.
- Also identified by DOI 10.1073/pnas.2527641122 and PMC identifier 12718390.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Neuropathic pain associated with central sensitization is common in diabetic patients, but the underlying mechanisms remain unclear. Here, a proteomics screen identified a previously uncharacterized protein, galectin-related protein (LGALSL), which was significantly upregulated in cerebrospinal fluid and extracellular fluid of the anterior cingulate cortex (ACC) in diabetes-related neuropathic pain (DNP) model rats. Exogenous LGALSL administration reduced mechanical nociceptive thresholds by activating glutamatergic neurons in the ACC (ACC<sup>Glu</sup>). Chemogenetic manipulations and functional assays revealed that neuron-derived LGALSL directly binds to vimentin on ACC astrocytes, activating those astrocytes. These activated astrocytes subsequently maintain ACC<sup>Glu</sup> hypersensitivity, driving mechanical hypersensitivity in diabetic rats. Blocking LGALSL-vimentin interactions with a synthetic peptide alleviated LGALSL-induced mechanical hypersensitivity. This study establishes LGALSL-dependent astrocyte-mediated hyperactivation of ACC<sup>Glu</sup> neurons as a new pathological mechanism of neuropathic pain in diabetes.
Medical subject headings
- Neuralgia
- Galectins
- Diabetes Mellitus, Experimental
- Diabetic Neuropathies